Department of Pulmonology, Democritus University of Thrace, Greece.
Crit Rev Oncol Hematol. 2013 Jul;87(1):90-100. doi: 10.1016/j.critrevonc.2012.12.003. Epub 2013 Jan 9.
Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification of molecular predictors of bleomycin toxicity on the aim to optimize individual use of bleomycin. We review all existing data on bleomycin's most recent integrated chemical biology, molecular pharmacology and mature clinical data and provide guidelines for its safe clinical use.
博来霉素是可治愈癌症（如霍奇金淋巴瘤[HL]和睾丸生殖细胞肿瘤[GCT]）治疗中有效化疗方案的关键组成部分，但它的使用可能会导致博来霉素诱导的肺损伤（BILI），这与显著的发病率和 1-3%的死亡率相关。BILI 的诊断需要排除其他因素，因此参与 HL 和 GCT 患者治疗的医生应保持警惕。药物基因组学研究可能有助于确定博来霉素毒性的分子预测指标，以优化博来霉素的个体化使用。我们回顾了博来霉素最近的综合化学生物学、分子药理学和成熟临床数据的所有现有数据，并为其安全的临床使用提供了指导方针。
